Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 720 results for pain management

  1. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

    Technology appraisal guidance
    Published
    24 July 2024

    Sections for TA989

  2. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)

    Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1018

  3. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

    Medtech innovation briefing
    Published
    4 March 2019

  4. Negative pressure wound therapy for the open abdomen (HTG321)

    Evidence-based recommendations on negative pressure wound therapy for the open abdomen. This involves using a small pump to remove infected material, stop fluid escaping and help the wound heal.

    HealthTech guidance
    Published
    27 November 2013
    View recommendations

    Sections for HTG321

  5. Referral criteria for joint replacement: What are the most important indicators that someone with osteoarthritis (including shoulder osteoarthritis) would benefit from joint replacement? For example: - presence of night pain - non-response to non-pharmacological interventions - joint instability symptoms - presence of flares - numerical summary scores.

    osteoarthritis) would benefit from joint replacement? For example: - presence of night pain - non-response to non-pharmacological...

    Research recommendation
    Published
    7 November 2022

  6. Ustekinumab for treating moderate to severe plaque psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  7. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

    Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.

    Technology appraisal guidance
    Published
    23 October 2024
    View recommendations

    Sections for TA1010

  8. Magseed for locating impalpable breast cancer lesions (MIB236)

    NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .

    Medtech innovation briefing
    Published
    17 November 2020

  9. Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)

    NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .

    Medtech innovation briefing
    Published
    14 December 2018

  10. Temporary dressings for up to 72 hours between wound excision and definitive soft tissue cover: What is the most clinically and cost effective temporary (up to 72 hours) dressing (including negative pressure dressings) for open fractures after wound excision for: - minimising the number of dressing changes or supplementary dressings - minimising the number of associated bedding changes - acceptability for patients, for example, in terms of minimising pain - minimising nursing time.

    changes - acceptability for patients, for example, in terms of minimising pain - minimising nursing time. Any explanatory notes(if...

    Research recommendation
    Published
    12 December 2022

  11. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA249

  12. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA357

  13. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

    Medicines practice guideline
    Last updated
    27 March 2017
    View recommendations

    Sections for MPG2

  14. Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)

    NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .

    Medtech innovation briefing
    Published
    27 July 2018

  15. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    are:- prevention or reversal of cachexia- overall survival- quality of life- pain relief- lean tissue mass- tolerance to treatment....

    Research recommendation
    Published
    14 November 2018